BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22

• 

  Series B

  Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform

  Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer.

  July 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  The 5 Largest Biopharma Layoffs of H1 2025

  The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS and Teva.

  July 10, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Government

  Kennedy Postpones Preventive Care Panel Meeting After ‘Double-Edged Sword’ Supreme Court Win

  The move has sparked concern that the U.S. Preventive Services Task Force could soon be dismissed after a decision by the high court affirmed Health Secretary Robert F. Kennedy Jr.'s power to remove its members at will.

  July 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short

  Partners Ultragenyx and Mereo BioPharma saw their stocks drop by 21% and 30%, respectively, after announcing that the Phase II/III study of their osteogenesis imperfecta candidate will proceed to final analysis, implying it did not show sufficiently strong results at an interim analysis.

  July 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B

  The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.

  July 10, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  IN PARTNERSHIP WITH ECLIPSEBIO

  The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines

  In this episode presented by Eclipsebio, BioSpace’s head of insights Lori Ellis discusses mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines, and Pad Chivukula of Arcturus Therapeutics.

  July 10, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Complete response letters

  FDA Publishes Cache of Complete Response Letters in Bid for ‘Radical Transparency’

  The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public insight into the reasons new drug and biologics applications got rejected.

  July 10, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Infectious disease

  Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership

  The Global Fund to Fight AIDS, Tuberculosis and Malaria will work with Gilead and other private backers to ensure the HIV preventive Yeztugo, approved last month by the FDA, is available in low- and middle-income countries, concurrent with high-income nations.

  July 10, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Arcus Biosciences Announces New Employment Inducement Grants - July 9, 2025

  July 10, 2025

   · 

  1 min read
• Press Releases

  Gozellix Receives Permanent HCPCS Code

  July 10, 2025

   · 

  9 min read